LMY-920 for Treatment of Relapsed or Refractory Myeloma
NCT05546723
Age 18 +
Sex Both
Phase Phase 1
Third Opinion Trial Synopsis
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. The study focuses on a combination of therapies that aim to improve patient outcomes and potentially offer a more effective treatment option. Here are some key details about the study:
- The treatment involves a combination of existing therapies that have shown promise in previous studies.
- Patients will receive a tailored treatment plan based on their individual health needs and responses to therapy.
- This study is unique because it combines multiple treatment strategies, which may enhance effectiveness compared to standard treatments.
- Researchers are closely monitoring the safety and effectiveness of the treatment, with regular assessments to ensure patient well-being.
- The study aims to gather data that could lead to new standards of care for patients with this condition.
Third Opinion AI Generated Synopsis
Trial Summary
Since CAR-T cell treatment of refractory myeloma has shown success, based on preclinical data, we posit that CAR-T cells expressing B-cell activating factor (BAFF) can become another strategy to treat refractory myeloma, even after relapse following BCMA targeting CAR-T cell treatment. This will be phase 1 study of BAFF ligand CAR-T cells in relapsed and refractory myeloma.
Since CAR-T cell treatment of refractory myeloma has shown success, based on preclinical data, we posit that CAR-T cells expressing B-cell activating factor (BAFF) can become another strategy to treat refractory myeloma, even after relapse following BCMA targeting CAR-T cell treatment. This will be phase 1 study of BAFF ligand CAR-T cells in relapsed and refractory myeloma.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
